ABSTRACT
Transient receptor potential canonical (TRPC) proteins constitute a family of seven (TRPC1-7) nonselective cation channels within the wider TRP superfamily. TRPC1, TRPC3, TRPC4, TRPC5 and TRPC6 channels are expressed in vascular smooth muscle cells from human vessels of all calibers and in smooth muscle from organs such as the uterus and the gastrointestinal tract. TRPC channels have recently emerged as important players in the control of smooth muscle function. This review will focus on the retrospective analysis of studies proposing contributions of TRPC channels to native calcium entry pathways in smooth muscle and to physiological and pathophysiological responses with emphasis on the vascular system.
CALCIUM SIGNALING IN SMOOTH MUSCLE CELLS

Calcium (Ca
2+
) ions impact nearly every aspect of cellular life and are considered universal intracellular messengers controlling a diverse range of cellular processes, including skeletal, cardiac and smooth muscle contraction, neuronal growth and neurotransmitter release (1; 2; 3). The spatial localization of Ca 2+ signals also contribute to increase the diversity of signals that can be successfully transmitted to downstream effectors (4). Vascular smooth muscle cells (SMCs) form a layer of contractile cells in the blood vessel wall and are known to be instrumental in maintaining the blood vessel structural integrity and regulating blood pressure and blood flow distribution (5; 6; 7). It is by the coordinated contraction and relaxation of these cells that the blood vessel diameter and stiffness can be modulated, thereby serving as one of the principal clinical control points for cardiovascular physiological parameters. In vascular SMCs, Ca 2+ signals have been suggested as modulators of cellular functions such as gene transcription, cell proliferation, contraction and phenotypic modulation that occur during vascular disease (5; 8; 9). Cytosolic Ca 2+ levels are carefully maintained at the hundred nanomolar range and Ca 2+ signals can be generated through Ca 2+ mobilization from either the intracellular stores (mainly the sarcoplasmic reticulum; SR) or the extracellular space. By means of Ca 2+ permeable channels and Ca 2+ pumps that mediate Ca 2+ entry and Ca 2+ extrusion/buffering respectively, SMCs keep intracellular Ca 2+ levels under tight control. The vascular tone or contractile state of the vessels is regulated through changes in the membrane potential of SMCs whereby membrane depolarization activates Ca 2+ entry through voltage-activated L-type Ca 2+ channels leading to activation of contractile proteins resulting in SMC contraction (10; 11). Physiologically, tone and contractility of vascular SMCs are controlled by cellular integration of a plethora of signals in response to vasoactive agonists. It is not unambiguously determined whether vascular reactivity in response to neuronal, humoral and endothelial factors is mediated directly by receptor-generated Ca 2+ entry or by the indirect activation of L-type Ca 2+ channels through Na + -mediated membrane depolarization resulting from receptor activation of non-selective cation channels.
Membrane receptors to vasoactive hormones and neurotransmitters (e.g. norepinephrine, angiotensin II and vasopressin) are typically coupled to G proteins resulting in the activation of isoforms of phospholipase C (PLC). The activation of PLC catalyzes the breakdown of phosphatidylinositol 4,5-bisphosphate (PIP 2 ) into two intracellular second messengers, Inositol 1,4,5-trisphosphate (IP 3 ) and Diacylglycerol (DAG) (12). These second messengers play a central role in Ca 2+ release from intracellular Ca 2+ stores and Ca 2+ entry from the extracellular space. Ca 2+ release from the SR is mediated by the action of IP 3 on its receptor (IP 3 R) located at the SR (12). The fall of the Ca 2+ concentration within the lumen of the SR (store depletion) is functionally coupled to the activation of Ca 2+ entry from the extracellular space via store operated Ca 2+ (SOC) channels (13; 14). This pathway was originally termed capacitative Ca 2+ entry (CCE) but is commonly referred to as store-operated Ca 2+ entry (SOCE) (13; 15; 16). The role of SOCE is to refill the stores and also to signal downstream to the nucleus. In SMCs, SOCE was proposed to meditate contractility as well as cell proliferation and migration (17; 18). The current mediating SOCE was first measured in rat basophilic leukemia (RBL) mast cells and termed Ca 2+ release-activated Ca 2+ (CRAC) current (19). CRAC channels exhibit low conductance, strong inward rectification and displays remarkable Ca In addition to the action of IP 3 , the increase in the intracellular Ca 2+ levels and the concomitant generation of DAG and other downstream metabolites of the phosphoinositide pathway such as Arachidonic Acid (AA) are known to directly mediate the activation of Ca 2+ entry from the extracellular space via Ca 2+ -permeable storeindependent cation channels that are referred to as Receptor-Operated channels (ROC), because their activation does not depend on the state of the stores and requires instead, actions of second messengers produced downstream of receptor activation (1; 13; 21; 22; 23). It is essential to recognize the fundamental distinction between the activation mechanisms and molecular identities of these two Ca 2+ entry pathways. Although both SOC and ROC channels function downstream of PLC, here we will refer to SOC channels under the strict definition where store depletion is necessary and sufficient for their activation without requirement for actions by Ca 2+ and other lipid second messengers.
CONTRIBUTION OF TRPC CHANNELS TO SMOOTH MUSCLE CALCIUM SIGNALS
The molecular identity of the SOCE pathway in different cell types and in SMCs in particular has been the subject of intense investigations for the past two decades, and remains to this day a highly controversial topic (5; 13; 24). One of the first molecular candidates proposed to encode SOC channels were mammalian transient receptor potential (TRP) channels, particularly members of the canonical family (TRPC), by virtue of their activation downstream of PLC-coupled receptors (25). The discovery of the TRP superfamily of cation channels was initially related to a channelopathy where drosophila flies with mutations in the TRP gene were found to have impaired vision due to the lack of a specific light-induced PLCdependent Ca 2+ entry pathway in photoreceptor cells (25; 26; 27; 28; 29). Normally in these cells, excitation by light is maintained and so is depolarization, as long as the stimulus (light) is present. Referring to the specific electric phenotype of mutant flies, where a normal but transient response was present due to failure to maintain depolarization upon light stimulation, this gene was called transient receptor potential or Drosophila TRP (25; 30; 31; 32; 33; 34; 35) . The discovery of the drosophila TRP gene eventually led to the identification of a number of TRP homologs in mammals (36) . TRPC channels represent one family among the six large families that constitute the TRP superfamily of cation channels, and are termed "classical" or "canonical" because they are structurally the closest to the founding family member, Drosophila TRP (37; 38). The mammalian TRPC family has seven members (TRPC1-TRPC7) out of the 28 members of the human TRP superfamily that have been identified so far. Based on structural homology, functional similarities and direct known interactions, the TRPC family can be divided into four subfamilies: TRPC1, TRPC2, TRPC3/6/7 and TRPC4/5 (or TRPC1 is sometimes included in the TRPC4/5 subfamily) (24; 37; 38). TRPC2, although a pseudogene in humans, is known to encode functional channels in most other mammals. (For a comprehensive review the reader is referred to (39) ). The seven mammalian TRPC cation channels share architectural compositions that can be summarized as follows: six transmembrane spanning regions (TM1-6), with a putative pore forming region between TM5 and TM6 (40) , and cytoplasmic N-and C-terminus where 3-4 ankyrin-like repeats (ANK1-4) and the invariant TRP signature motif (EWKFAR) are located respectively (38; 41; 42) .
Since their discovery, all the TRPCs have been suggested to encode SOC and ROC channels, based on their participation in Ca 2+ entry routes that were initially shown to be activated downstream of PLC-coupled receptors (24; 38; 41; 42; 43; 44) . Ironically, it is now clear that the mechanism by which the Drosophila TRP is activated in its native environment in photoreceptor cells is independent of store depletion (45) . Notwithstanding this evolutionary conundrum, a large body of evidence in the past decade supported a role for TRPC channels as SOCs in a variety of mammalian cell types including SMCs and endothelial cells (ECs) from different vascular beds (for reviews (13; 24; 44)). However, a large number of laboratories, including our own showed that TRPCs do not function as SOCs when ectopically expressed in HEK293 cells and that native SOCE in SMCs and ECs functions independently of TRPC channels (14; 18; 24; 46). In fact, the past 4-5 years yielded significant advancements regarding the molecular composition and the activation mechanism of SOC channels and had a remarkable impact in revitalizing the quest for understanding SOC regulation. Using RNA interference (RNAi)-based high throughput screens combined with the SERCA pump blocker thapsigargin to passively deplete the stores, four independent groups clearly identified two conserved genes encoding proteins that are required for SOCE in drosophilae Shneider2 (S2) 
TRPC CHANNELS AND VASCULAR SMOOTH MUSCLE PHENOTYPIC MODULATION
Vascular SMCs express a large repertoire of ion channels that are critical to translate physiological stimuli into critical cellular functions such as contraction, migration and proliferation (5; 72). In normal conditions, SMCs within the adult vasculature are characterized by an extremely low rate of proliferation, very low synthetic activity and a unique repertoire of ion channels, contractile proteins and signaling molecules that are all required for their proper function (5; 6; 73). However, it is known that cell type-specific channel profiles exist between smooth muscle cells residing in different anatomical locations, and that this specific channel expression profile is critical when defining the phenotypic identity of the smooth muscle cell (7; 74). Unlike cardiac and skeletal myocytes that are terminally differentiated, vascular SMCs retain remarkable phenotypic plasticity that is responsive to humoral, environmental and pathophysiological cues. Dedifferentiation from the quiescent phenotype to the synthetic one is accompanied by adaptive changes in expression profile of different ion channels, transporters and Ca 2+ binding proteins that provides the cell with means to support its new proliferative and migratory phenotype. This phenotypic modulation or switching from a contractile to a synthetic phenotype can be seen upon vascular injury and in various vascular disease states such as atherosclerosis and hypertension. Synthetic vascular SMCs downregulate the expression of L-type voltage gated Ca 2+ channels and concomitantly increase the expression of the low voltage-activated (T-type) Ca 2+ channels and TRPC channels (5) . Recent studies have suggested that Ca 2+ -responsive pathways are responsible for transcriptionally regulating their own components whereby a Ca 2+ entry via a specific Ca 2+ channel is capable of activating the transcription of this channel's mRNA as recently described for TRPC6 channels (75) . Thus, TRPC channels, which are upregulated in synthetic SMCs, may activate proproliferative pro-migratory downstream signaling pathways in vascular SMCs and control the transcriptional regulation of the Ca 2+ responsive components of these pathways. Evidence for a functional role of TRPC channels in mediating vascular SMC phenotypic modulation in disease will be discussed later in this review.
ACTIVATION MECHANISMS OF TRPC CHANNELS IN SMOOTH MUSCLE
TRP channels are expressed in almost every tissue and cell type, where they play unique roles as cellular sensors and signal integrators of a plethora of Ca 2+ -mediated cellular functions (76; 77) . In the vasculature, all seven members of the TRPC family of cation channels are expressed. TRPC1, and TRPC3 through TRPC6 channels are widely expressed in human vessels of all calibers, from the largest conduit vessels to medium size coronary arteries, cerebral arteries, smaller size resistance arteries and vaso vasorum, where they were proposed to mediate physiological and pathophysiological cellular responses (78) . With the exception of a study reporting a role of a channel formed by heteromultimeric association between TRPC6 and TRPC7 that is activated by vasopressin in A7r5 smooth muscle cell line (79), the expression of TRPC7 has been found in endothelial cells but not in vascular SMCs. The founding member of the canonical TRP family is TRPC1, which was the first mammalian TRP member to be cloned (41; 80; 81) . TRPC1, which is found in vascular SMCs of several species, is widely but not uniformly expressed in all types of vascular beds (78; 82; 83) . The proposed physiological roles of TRPC1 include contributions to critical functions such as vascular SMC contraction and proliferation (36; 83; 84; 85; 86) . The discovery of TRPC1 in the vasculature led to the hypothesis that this channel was the long sought vascular SOC channel. Subsequently, many researchers have proposed that TRPC1 contributes to SOCE in vascular SMCs from many vascular beds in several species such as human, dog, mouse, rabbit and rat (82; 83; 87; 88; 89; 90) . A great part of the accumulated knowledge on the functional properties of TRPC1 has been acquired from studies in which the function of the endogenous protein was impaired by treatment with an antibody against an extracellular loop of the putative pore forming region (82; 91) or by the use of antisense DNA and RNAi targeting TRPC1 mRNA (89; 90; 92) . Interestingly, the outcomes of all the studies when focusing on vascular SMCs converge in that these treatments were able to only marginally inhibit SOCE activated by thapsigargin or cyclopiazonic acid (CPA). For example, Xu et al showed that using an antibody targeting the putative pore forming region of TRPC1 inhibited SOCE by ~15% (82) . An exception is the study by Takahashi et al which reported the abrogation by ~60% of SOCE in response to thapsigargin in coronary artery SMCs treated with RNAi against TRPC1, as compared to control (88) . In a concurrent study, these authors reported that mediation of SOCE by TRPC1 occurs in a STIM1-dependent manner in human coronary artery smooth muscle cells (93) . However, the contribution of membrane depolarization, Ca 2+ -activated channels and voltage-gated channels to the overall Ca 2+ signal in these cells is unclear. In fact, a general observation in most of the studies suggesting a role for TRPC channels in SOCE is the lack of current recordings in the presence of strong buffering to rule out contributions from Ca 2+ -activated currents. At the very least, Ca 2+ measurements under voltage clamp conditions or the use of protocols with voltage-gated channel inhibitors are necessary to support the Ca 2+ imaging measurements (54) . Another complication of Ca 2+ measurements is the potential generation of recordings artifacts by the use of SERCA blockers such as thapsigargin and CPA, which by compromising the buffering capacity of the ER/SR might exaggerate the constitutive -not regulated-activity of Ca 2+ entry through a TRPC channel (94) (discussed in detail in (37) ). Despite the large body of evidence supporting a role of TRPC1 (and other TRPC) channels in SOCE, an equal amount of studies from many independent investigators failed to detect any role for TRPC proteins in SOCE. Briefly, studies by Dietrich et al have showed that smooth muscle cells isolated from aorta and cerebral arteries of TRPC1 knockout mice possess SOCE currents that were comparable to those recorded in cells from wild type mice (69) . Recently, DeHaven et al clearly demonstrated that the function of TRPC1, TRPC3, TRPC5, TRPC6 and TRPC7 does not depend on STIM1 (71) . Another limitation in studies investigating the role of TRPC1 is the discrepancy between results from different groups when TRPC1 was ectopically expressed in cell lines (60) . Although some laboratories reported functional TRPC1 channels at the plasma membrane following TRPC1 ectopic expression, other groups have demonstrated the need of co-expression with other TRPC isoforms for the proper trafficking of TRPC1 to the plasma membrane. A rigorous study by Hofmann et al have showed that interactions of TRPC1 with TRPC4 and TRPC5 appear to be necessary to translocate TRPC1 to the plasma membrane, as assessed by four independent experimental approaches (95). Additionally, the interactions of TRPC1 with other TRPC members provide these heterotetrameric channels with unique biophysical properties distinct from channels formed as homotetramers (96) .
The difficulty in reconciling TRPC channel properties with SOCE has been critically evaluated elsewhere (97) , and in general, a less contentious topic is that physiological TRPC1 activation is achieved downstream of PLC activation by still a yet unknown mechanism.
It is well accepted that under physiological conditions, TRPC4/5 channels are activated downstream of PLC-coupled receptors, are insensitive to DAG and IP 3 but show clear requirement of PLC activation (98 (112) . However, other studies on channels formed by TRPC4 and TRPC5 have shown receptor-activated rather than storeoperated regulation (100; 101; 102) (for review see (113)). Ulloa et al recently showed that human myometrium expresses TRPC4, TRPC1 and TRPC6 mRNAs and demonstrated a store-independent contribution of TRPC4 channels to receptor-activated Ca 2+ entry (in response to oxytocin, ATP and PGF2α) in PHM1-41 cells and primary human uterine SMCs (114) . More recently, non-selective receptor-operated store-independent TRPC4 cation conductances were reported in response to acetylcholinemediated muscarinic receptor activation in gastrointestinal SMCs (115) .
Like all TRPC members, the TRPC3/6/7 subfamily forms Ca 2+ -permeable non-selective cation channels that are activated through PLC-coupled receptors and display both, inward and outward rectification with reversal potentials around 0mV. The cation permeability ratios p Ca /p Na for TRPC3/6/7 range from 3 to 6, indicating nonselective behavior (37; 38; 116) . It is widely accepted that TRPC3/6/7 are activated by DAG analogs in a PKCindependent manner providing a plausible mechanism for their activation through PLC-coupled receptors (61; 68; 117; 118) . Furthermore, studies from our laboratory showed that endogenous DAG is sufficient to activate TRPC3 channels independently of IP 3 , IP 3 R, G proteins and store depletion (68) . Treatment of cells with phorbol esters inhibited the DAG analog 1-oleyl-2-acetyl-snglycerol (OAG)-mediated activation of the TRPC3/6/7 subfamily suggesting negative regulation rather than signal mediation via PKC (68; 117; 118) . This negative regulation exerted by PKC occurs via serine712 phosphorylation on TRPC3 channels (119) . While it is clearly established that diacylglycerol (DAG) produced through Phospholipase Ccoupled receptor stimulation and structural analogs such as OAG activate TRPC3/6/7, the exact mechanisms of activation of these channels by DAG remains unknown. Furthermore, it appears that TRPC3/6/7 channels require PIP 2 for their proper activation by DAG analogs (120). TRPC6 is the major TRPC expressed in vascular SMC and the most widely studied. TRPC6 is the only TRPC channel that has not been described as SOC; when ectopically expressed, both human and mouse isoforms of TRPC6 behave as a non-selective cation channels whose activation downstream of PLC is independent of intracellular Ca 2+ store depletion (61; 116; 121). Kim and Saffen showed that an equivalent residue to the serine 712 identified in TRPC3 was present in rat TRPC6 and was implicated in the PKCmediated phosphorylation and negative regulation of TRPC6 channels (122) . As will be discussed below, under physiological conditions TRPC6 channels appear to mediate the effects of vasoactive compounds in vascular SMCs (121; 123; 124). (124) . A good amount of evidence suggests TRPC1 contribution in mediating the vascular action of vasoactive peptides, hormones and neurotransmitters. Saleh et al reported that in freshly isolated rabbit mesenteric artery smooth muscle cells, low and high concentrations of angiotensin II are capable of activating two conductances that were inhibited by an AT1 receptor inhibitor and by antibodies against TRPC1 and TRPC6 (125). Moreover, Bergdahl et al have shown that treatment of caudal arteries with a TRPC1 antibody inhibited endothelin-1-induced vasoreactivity and vascular SMC contraction (126) . In studies focusing on a canine model of cerebral vasospasm after subarachnoid hemorrhage (SAH), a novel mechanism involving endothelin-1-mediated acute elevations in intracellular Ca 2+ and severe basilar artery constriction have been described (127) . Treatments of SAH arteries with antibodies targeting either TRPC1 or TRPC4 were capable of inhibiting endothelin-1-induced Ca 2+ entry and vasoconstriction (127) . In rat aortic SMCs, the Ca 2+ signal elicited by endothelin-1 was also inhibited by RNAi targeting TRPC1 (128) . Although TRPC4 is found widely expressed in vascular SMCs and endothelial cells from human vascular beds and different size arteries, its contribution to SMC physiology is not well defined (86; 103). Studies in TRPC4 -/-mice have shown deficiencies in endothelialdependent SMC relaxation but interestingly its contribution to the SMC contractile response is unclear (105) . TRPC4, along with TRPC6, have been proposed however to play an in vivo role in gastrointestinal motility through control of SMC contraction (115); nonselective cationic currents contributed by TRPC4 and TRPC6 channels were shown to be activated through muscarinic receptor stimulation in intestine SMCs. It was suggested that the acetylcholineactivated nonselective TRPC currents thus generated would cause depolarization of intestine SMCs with subsequent Ltype Ca 2+ channel activation and contraction (115) . Similarly, it was reported by Walker et al that membrane depolarizing currents, causing Ca 2+ entry through voltagegated Ca 2+ channels, had a similar current-voltage ) and Diacylglycerol (DAG). IP 3 -mediated Ca 2+ store depletion activates store-operated Orai1 channels in a mechanism dependent on STIM1 aggregation and translocation into areas of close SR-PM contacts. The role of TRPC channels in mediating SOC channels remains to this day a highly contentious issue. All TRPC are activated by mechanisms downstream of PLC; TRPC3/6/7 have been shown to be activated by DAG in a PKC independent manner while TRPC1/4/5 exact mechanisms of activation via membrane receptors is still unclear and seems to involve PIP 2 breakdown and Ca
TRPC CHANNELS IN VASCULAR PHYSIOLOGY
Blood flow regulation is mainly achieved by the integration of signals conveyed by vasoactive compounds such as norepinephrine, vasopressin, endothelin-1 and angiotensin II, which upon stimulation of vascular SMC membrane receptors regulate the vascular tone. Many studies have suggested a role for TRPC channels as components of this physiologically relevant pathway
2+
. Na + entry through nonselective TRPC channels has been proposed to couple to activation of Ca 2+ (Figure 1 ). Despite efforts aimed at elucidating the mechanisms of regulation and activation of TRPC5, little is known about its physiological relevance in SMCs. The involvement of TRPC5 in the control of vascular SMC motility through cellular sensing of sphingosine 1-phosphate has been proposed (137). TRPC5 appears to form a functional channel in arteriolar smooth muscle cells, where Xu et al characterized a TRPC1/TRPC5-like heteromultimeric currents activated by store depletion and inhibited by an antibody targeting TRPC5 (112) . Moreover, another study has identified a TRPC5-like current upon activation of muscarinic receptors in SMCs from the stomach and suggested TRPC5 as the non-selective cation channel activated by agonists such as acetylcholine (138) .
TRPC3 mRNA expression pattern suggests that this nonselective cation channel is mostly expressed in embryonic brain and cardiac tissues (81; 139) . While TRPC3 expression has been found in vascular SMCs, no clear physiological function has been assigned or correlated with its expression (85) . It is now appreciated that TRPC3 has substantial constitutive activity (140) , that may confer to this channel the ability to modulate basal SMC contractility through control of membrane potential and regulation of the activity of L-type Ca 2+ channels. Along those lines, antisense DNA targeting TRPC3 mRNA inhibited depolarization and vasoconstriction of intact cerebral arteries induced by uridine 5'-trisphosphate (UTP). Treatment with antisense DNA targeting TRPC3 also inhibits UTP-evoked whole cell currents when measured in isolated SMCs (141) . Compared to TRPC6, TRPC3 displays higher spontaneous activity and thus might play a prominent role in smooth muscle tonicity (140) . The ability of TRPC3 to form heteromultimers with other TRPC channels might generate a higher capacity of tonic cation entry and chronic smooth muscle contraction that could contribute to vascular pathologies such as hypertension (142) . Further insights into the role of TRPC3 in vascular SMC physiology were gained from studies with knockout mice. TRPC6 knockout (TRPC6 -/-) mice showed compensatory increase in TRPC3 expression in SMCs from aorta and cerebral artery causing vascular hypercontractility and elevated blood pressure (143) . Vascular SMCs from these TRPC6 -/-mice showed a more depolarized membrane potential accompanied by an enhanced spontaneous and agonist-induced Ca 2+ entry and contraction (143) . The constitutive nature of TRPC3 activity suggests that physiologically, this channel might be responsible for basal smooth muscle tone regulation. The physiological relevance of TRPC6 channel was apparent when Inoue et al reported convincing biophysical and pharmacological similarities between ectopically expressed TRPC6 in HEK293 cells and the native non-selective cation conductance activated upon α1-adrenoreceptor stimulation in rabbit portal vein smooth muscle cells (121; 144) . In addition, vasopressin stimulation in the aortic SMC line A7r5 activated membrane conductances that depended on TRPC6 (79; 133; 145; 146) . Subsequently, other studies have suggested that TRPC6 is activated in response to other physiologically relevant vasoactive peptides such as angiotensin II. Saleh et al reported TRPC6 activation upon stimulation with angiotensin II of vascular SMC isolated from rabbit mesenteric artery (125) . In afferent arterioles, Ca 2+ entry thought to elicit arteriolar contraction in response to treatment with angiotensin II was dependent on TRPC6 and reverse mode function of NCX (134) . It was proposed that the arterial myogenic response known as Bayliss effect, or the inherent capacity of vessel constriction to avoid hemodynamic changes following elevated intravascular pressure, is in part TRPC6-dependent (147) . This function of TRPC6 was proposed to be mediated indirectly through depolarization and activation of Ca 2+ influx via voltage-gated Ca 2+ channels. Finally, a member of the larger TRPM family, TRPM4 was also proposed to contribute in a similar manner to the contractile response of vascular SMCs (148) , but the precise function of TRPM4 channels in SMCs requires further investigation. Cellular growth and proliferation is one of the many cellular functions that are regulated by TRPC channels. In pulmonary artery SMCs, PDGF-mediated cellular proliferation is associated with c-jun/STAT3-mediated transcription and up-regulation of TRPC6 expression (149) .
IMPLICATIONS OF TRPC CHANNELS IN VASCULAR DISEASE
The phenotypic change of vascular SMC from quiescent to synthetic is thought to be an integral part of the pathophysiological response of SMCs and is of paramount importance in the development of vascular disease. For instance, upon vascular injury the expression of TRPC channels is upregulated and is believed to take part in the definition of the proliferative migratory state of synthetic vascular SMCs (5; 123; 150). Specifically, TRPC1 has been implicated in mediating several SMC pathologies such restenosis, pulmonary hypertension and atherosclerosis (5; 85). The pathophysiological relevance of TRPC1 upregulation was assessed in a human saphenous vein organ culture where intimal structures containing SMCs expressed higher levels of TRPC1 compared to medial layer cells (91) . In this study, the use of an antibody targeting the putative pore-forming region of TRPC1 was able to significantly inhibit the extent of neointima formation, Ca 2+ entry and vascular SMC proliferation (91) . Similarly, upon vascular injury by balloon dilatation in the internal mammary artery TRPC1 expression was enhanced (123). Golovina et al have reported that in proliferative human pulmonary artery smooth muscle cells, TRPC1 protein expression as well as SOCE was increased as compared to non-proliferative cells (87) . Unpublished results from our laboratory showed that rat aortic synthetic SMCs have upregulated levels of TRPC1 and TRPC6 compared to quiescent freshly isolated SMCs. Takahashi et al showed that in cultured coronary artery SMCs, TRPC1 expression increased upon angiotensin II stimulation while that of TRPC3/4/5/6 was not affected and suggested that angiotensin II-induced vascular SMC hypertrophy, which is one of the major events leading to atherosclerosis, is mediated through NF-κB-induced increase in TRPC1 and subsequent Ca 2+ entry (88). Here we should point out that the correlative increase in SOCE and TRPC expression reported in proliferative SMCs by the studies mentioned above can be equally explained by increased expression in synthetic SMCs of the newly discovered SOCE machinery (STIM1 and Orai1 proteins) reported by our group and others (18; 150). Indeed, studies from our laboratory showed that protein levels of STIM1 and Orai1 are significantly increased in synthetic SMCs compared to quiescent cells (18) as well as in neointimal SMCs from rat carotids subjected to balloon angioplasty (Unpublished results). Furthermore, we showed that the increase in SOCE in synthetic SMCs was inhibited upon either STIM1 or Orai1 protein knockdown, while individual or combined protein knockdown of TRPC1/4/6 did not affect the extent of SOCE activation (18). We also showed that protein knockdown of STIM1 and Orai1 inhibited synthetic SMC migration and proliferation while protein knockdown of STIM2, Orai2 and Orai3 were without effect, suggesting a selective role of STIM1/Orai1 in SMC proliferation and migration. The in vivo relevance of STIM1 in vascular disease was recently demonstrated in two studies showing that in vivo knockdown of STIM1 using viral particles encoding STIM1-targeted shRNA in rat balloon-injured vessels inhibited neointima formation (151; 152).
Pulmonary hypertension refers to an increased blood pressure in the pulmonary circulation and can be triggered either by decreased in cardiac function or by exposure to hypoxic conditions. Exposure of the pulmonary vasculature to low levels of oxygen evokes a physiological response whereby pulmonary vasculature constriction orchestrates the optimization of blood oxygenation. Hypoxic pulmonary vasoconstriction is characterized by chronic episodes of alveolar hypoxia whereby hypoxic episodes promote acute constriction of the pulmonary vasculature, to minimize ventilation-perfusion mismatch and optimize oxygenation and gas exchange in the lung (153; 154) . However, prolonged exposure to hypoxia evokes a series of arterial structural changes that subsequently elevate the pulmonary vascular resistance leading to development of pulmonary hypertension and ultimately, right heart failure (155) . One of the hallmarks of severe pulmonary artery hypertension is the arterial hypertrophy that arises due to excessive pulmonary artery smooth muscle cell proliferation. The excessive vascular remodeling observed in hypoxic pulmonary hypertension is accompanied by distortional Ca 2+ homeostasis in pulmonary artery SMCs believed to play a central role in the development of the disease (92; 156; 157; 158) . Studies with isolated proliferative pulmonary artery SMCs treated with antisense oligonucleotides targeting TRPC1 mRNA were able to decrease Ca 2+ entry and SMC proliferation (87; 90). These findings suggest that TRPC1 might be a potential target for therapy of pulmonary hypertension. In pulmonary artery SMCs isolated from rats exposed to chronic hypoxic conditions for three weeks, the levels of TRPC1 and TRPC6 expression as well as Ca 2+ entry in response to either passive store depletion or agonits was increased (92; 159) . In a rat model of hypoxia-induced pulmonary hypertension TRPC1 and TRPC6 upregulation was shown to be mediated by hypoxia inducible factor 1 (HIF-1) and exposure of mice heterozygous for HIF-1 to hypoxic conditions failed to increase TRPC1 expression (157) . The upregulated expression of TRPC1 and TRPC6 observed in this animal model of hypoxic pulmonary hypertension is accompanied by increased basal and agonist-induced Ca 2+ entry in pulmonary SMCs (156; 157) . Similarly, Lin et al showed that TRPC6 expression was upregulated in pulmonary artery SMCs isolated from rats with hypoxic pulmonary hypertension (92) . In this study, OAG-induced cation entry recorded in pulmonary artery SMCs from hypoxic rats was significantly increased when compared to cells isolated from control normoxic animals (92). Zhang et al suggested that a low-dose of ATP exerts part of its mitogenic effect in human pulmonary artery SMCs through CREB-mediated upregulation of TRPC4 channel expression and subsequent increase in Ca 2+ influx. In this study treatment with ATP markedly increased TRPC4 expression through CREB phosphorylation, suggesting a possible role of TRPC4 in vascular remodeling during pathophysiological responses and its contribution to development of pulmonary hypertension (111) . In pulmonary artery endothelial cells, exposure to hypoxia causes increase in TRPC4 expression and the transcription factor AP-1 binding activity (160) . These authors proposed that hypoxia increases AP-1 binding activity by enhancing Ca 2+ influx through TRPC4 channels in human pulmonary endothelial cells and that Ca 2+ -mediated increase in AP-1 binding may upregulate expression of growth factors that would, in turn, stimulate pulmonary vascular remodeling in patients with hypoxiainduced pulmonary hypertension. Therefore, TRPC4 contribution to vascular pathophysiology might be more complex involving changes in endothelium-dependent SMC signaling.
The role of TRPC5 in the development of vascular disease has been less defined and little is known about its exact contribution. Nonetheless, it has been shown that TRPC5 homomultimers as well as TRPC1/5 heteromultimers are activated in response to sphingosine-1-phosphate, a signaling phospholipid that accumulates in atherosclerotic lesions (137) . In this study, sphingosine-1-phosphate was found to stimulate motility of SMCs isolated from human saphenous vein and this action was inhibited by pre-treatment of cells with the E3-targeted anti-TRPC5 antibody or by disrupting the normal function of the channel by the use of a TRPC5 pore mutant (137) . Pulmonary artery SMCs from patients suffering from idiopathic pulmonary arterial hypertension (IPAH) are characterized by hyperproliferative behavior and show upregulation of TRPC isoforms: TRPC3 and TRPC6 (161; 162) . In these cells, proliferation and TRPC6 expression were strongly attenuated by the use of RNAi specifically targeting TRPC6 (161) . Moreover, it has been reported that the endothelin receptor blocker bosentan, an antiproliferative agent currently used for treatment of IPAH, significantly downregulate TRPC6 expression likely through a mechanism independent of endothelin receptor blockade (163) . In a follow up study, this group identified a single-nucleotide polymorphism (SNP) 254 (C G) in the TRPC6 gene promoter that created a binding sequence for the inflammatory transcription factor NF-κB and suggested that the 254 (C G) SNP may predispose individuals to an increased risk of IPAH by linking abnormal TRPC6 transcription to nuclear NF-κB. The 254 (C G) SNP enhanced nuclear NF-κB-mediated promoter activity and stimulated TRPC6 expression in pulmonary artery SMCs while inhibition of nuclear NF-κB activity attenuated TRPC6 expression and decreased agonist-activated Ca 2+ influx in pulmonary artery SMCs from IPAH patients harboring the 254G allele (164) The in vivo relevance of TRPC isoforms extends to resistance arteries where they are implicated in the pathology of secondary hypertension. In deoxycosticosterone acetate (DOCA)-salt hypertensive rats, hypertension is thought to be developed due to an increased in agonist-mediated vascular SMC contractility that leads to chronic elevation of blood pressures (165) . Studies on mesenteric arteries isolated from DOCA-salt sensitive rats display enhanced serotonin and norepinephrine-induced cation currents that are absent in control normotensive rats. This increased in cation current activity correlated with concomitant increase in TRPC6 expression; the expression of TRPC1/3 channels was not affected (166 (168) . Xiao et al recently showed that TRPC1 and TRPC3 proteins and mRNAs were expressed in freshly isolated airway smooth muscle tissues. Using blocking antibodies and RNAi against TRPC1 and TRPC3 they proposed TRPC3 as an important component of native nonselective cationic channels in airway smooth muscle. TRPC3 blockade inhibited the nonselective cationic currents and caused membrane hyperpolarization in airway SMCs. In the same study, increased TRPC3 expression appears to mediate membrane depolarization and hyperresponsiveness in an animal model of asthma where airway SMCs are sensitized by ovalbumin; TRPC1 channels were also proposed to contribute to nonselective cationic currents in ovalbuminsensitized/challenged airway SMCs (114) . To date, a potential pathophysiological role for TRPC7 within the vasculature remains unknown. TRPC7 involvement in apoptosis has been reported in two different cell systems (169; 170), but whether TRPC7 plays a role in SMC hyperplasia characteristic of vascular disease remains to be investigated.
CONCLUSION
The proposed mechanisms of activations of TRPC channels are depicted in Figure  1 . Table 1 summarizes tissue distributions and SMC pathologies where TRPC channels are involved. It is clear from the studies discussed above that TRPC channels have a farreaching role in both physiological and pathophysiological functions of SMCs in the pulmonary and systemic cardiovascular system. Additional roles for TRPC channels in SMCs from other organs such as the gastrointestinal tract, uterus and bladder are beginning to emerge. The upregulation of TRPC channels in SMCs, especially that of TRPC1 and TRPC6, in conditions of systemic and pulmonary hypertension and vascular remodeling suggests a major role of these proteins in the abnormal SMC proliferation and contractility characteristic of these diseases. Future TRPC channels blockers are likely to be beneficial in the therapeutic control of SMC function during various vascular pathologies.
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